ClinicalTrials.gg
CompletedNCT04601051Updated Jan 30, 2026

Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of NTLA-2001 in Patients With Hereditary Transthyretin Amyloidosis With Polyneuropathy (ATTRv-PN) and Patients With Transthyretin Amyloidosis-Related Cardiomyopathy (ATTR-CM)

A Phase 1 interventional study of NTLA-2001 in Transthyretin-Related (ATTR) Familial Amyloid Polyneuropathy, Transthyretin-Related (ATTR) Familial Amyloid Cardiomyopathy and Wild-Type Transthyretin Cardiac Amyloidosis, sponsored by Intellia Therapeutics. Completed at 4 sites in 4 countries. Open to participants aged 18 Years to 90 Years. Per ClinicalTrials.gov, last updated 2026-01-30.

Sponsored by Intellia Therapeutics · Phase 1, Interventional, and Treatment

How we know

From the registry’s dates

  • Primary completion was Sep 2025, 1 year 2 months ago, and no results have been posted to the registry.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
72
Allocation
Non-randomized
Ages
18 Years to 90 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 35 studies in Amyloid Neuropathies, Familial with a site in France — 15 open to participants now, 16 under way, 1 of them phase 3. Amyloid Neuropathies, Familial · France.

Enrollment
15th of 23
72 · median 128
Started
2020
with 5 others
Phase 1
2 of 35
none open now
Registered
19th of 35
by date
Lead sponsor
2 of 35
Intellia Therapeutics

Among the 35 studies in Amyloid Neuropathies, Familial with a site in France, this one is the 15th largest by enrollment of the 23 interventional ones that give a count, is one of 6 that started in 2020, is one of 2 in phase 1, and was the 19th registered.

Amyloid Neuropathies, Familial

188 studies on the registry are indexed under Amyloid Neuropathies, Familial; 94 are open to participants now.

Browse Amyloid Neuropathies, Familial studies →

Open to participants now

15 of the 35 studies in Amyloid Neuropathies, Familial with a site in France are open now. Recruiting first, the newest first:

10 more — sign in →

All 15 open studies →

A study can be open while its sites in France have not opened yet or have stopped. Only those recruiting at a site in France →

Who these studies take

Of the 69 Amyloid Neuropathies, Familial studies recruiting now, 53 (77%) set no upper age limit and 1 (1%) stops at 75 or younger; 7 take children under 18; 9 take healthy volunteers.

This study: 18 Years to 90 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 35 studies in Amyloid Neuropathies, Familial with a site in France, or all of them as a file.
02

Study summary

This study will be conducted to evaluate the safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of NTLA-2001 in participants with hereditary transthyretin amyloidosis with polyneuropathy (ATTRv-PN) and participants with hereditary transthyretin amyloidosis with cardiomyopathy (ATTRv-CM) or wild type cardiomyopathy (ATTRwt-CM)

Read the detailed description

For ATTRv-PN participants, Part 1 consists of an open-label, single-ascending dose study, which identifies the dose for evaluation in the cohort expansion of Part 2. Part 2 will follow as an open-label, dose expansion study to further characterize the activity of NTLA-2001, provide an initial assessment of the effect of NTLA-2001 on clinical measures of neuropathy and neurological function, and obtain additional safety data.

For ATTR-CM participants, Part 1 consists of an open-label, single-ascending dose study, which identifies the dose for evaluation in the cohort expansion of Part 2. Part 2 will follow as an open-label, dose expansion study to further characterize the activity of NTLA-2001, provide an initial assessment of the effect of NTLA-2001 on cardiac measures, and obtain additional safety data.

All participants who are dosed with NTLA-2001 will be offered to participate in a long-term safety monitoring follow-up study via a separate protocol.

03

Conditions studied

  • Transthyretin-Related (ATTR) Familial Amyloid Polyneuropathy
  • Transthyretin-Related (ATTR) Familial Amyloid Cardiomyopathy
  • Wild-Type Transthyretin Cardiac Amyloidosis

Keywords

  • NTLA-2001
  • Pharmacokinetics
  • Pharmacodynamics
  • Neurologic Function
  • Clustered Regularly Interspaced Short Palindromic Repeats
  • CRISPR
  • Polyneuropathy
  • ATTR
  • Transthyretin
  • TTR
  • Amyloidosis
  • Familial Amyloid Polyneuropathy
  • FAP
  • Cardiomyopathy
04

Who can participate

Ages eligible
18 Years to 90 Years
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Polyneuropathy Inclusion Criteria:

  • Male and/or female participants 18 to 80 years of age inclusive, at the time of signing the
  • Diagnosis of polyneuropathy (PN) due to transthyretin (TTR) amyloidosis (ATTR)
  • Must have a body weight of at least 45 kilograms (kg) at Screening visit
  • Lack of access to approved treatments for ATTR and/or progression of hereditary transthyretin amyloidosis with polyneuropathy (ATTRv-PN) despite use of approved treatment for ATTRv-PN

Polyneuropathy Exclusion Criteria:

  • Amyloidosis attributable to non-TTR protein, e.g., amyloid light-chain (AL) amyloidosis
  • Known transthyretin amyloidosis
  • Use of any of the following TTR-directed therapy for ATTR within certain timeframe:

    1. Patisiran
    2. Inotersen
    3. Vutrisiran
    4. Tafamidis
    5. Diflunisal
    6. Doxycycline and/or tauroursodeoxycholic acid
    7. Any other agent for the treatment of ATTRv-PN:
  • Other protocol defined Inclusion/Exclusion criteria may apply

Cardiomyopathy Inclusion Criteria (UK only):

  • Male and/or female participants 18 to 90 years of age inclusive, at the time of signing the informed consent
  • Diagnosis of transthyretin (ATTR) amyloidosis with cardiomyopathy, classified as hereditary ATTR amyloidosis with cardiomyopathy (ATTRv-CM) or wild type cardiomyopathy (ATTRwt-CM).
  • Must have a body weight of at least 45 kilograms (kg) at Screening visit
  • (NYHA) Class I-III heart failure
  • At least 1 prior hospitalization for heart failure and/or clinical evidence of heart failure.
  • Able to complete ≥150 meters on the 6-minute walk test (6-MWT) during the Screening period.

Cardiomyopathy Exclusion Criteria (UK only):

  • Amyloidosis attributable to non-TTR protein, e.g., amyloid light-chain (AL) amyloidosis
  • Known leptomeningeal transthyretin amyloidosis
  • Use of any of the following TTR-directed therapy for ATTR within certain timeframes:

    1. Patisiran
    2. Inotersen
    3. Vutrisiran
    4. Tafamidis
    5. Diflunisal
    6. Doxycycline and/or tauroursodeoxycholic acid
    7. Investigational TTR stabilizer (e.g., AG-10)
  • Participants with heart failure that in the opinion of the investigator is caused by ischemic heart disease, hypertension, or uncorrected valvular disease and not primarily due to transthyretin amyloid cardiomyopathy.
  • Participants with a history of sustained ventricular tachycardia or aborted ventricular fibrillation or with a history of atrioventricular (AV) nodal or sinoatrial (SA) nodal dysfunction for which a pacemaker is indicated but will not be placed. Pacemaker or defibrillator placement, initiation of or change in anti-arrhythmic medication within 28 days prior to study drug administration.
  • Other protocol defined Inclusion/Exclusion criteria may apply
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Leptomeningeal disease

Cancer that has spread to the leptomeninges, the thin layers covering the brain and spinal cord, and the fluid between them. It is not the same as brain metastases.

Criteria often treat it separately, and many studies leave it out even where treated brain metastases are allowed.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
72 participants (actual)

Study arms

  • Experimental
    Polyneuropathy Part 1: NTLA-2001

    Participants, assigned to one of 4 dose-escalation cohorts, will receive a single dose of NTLA-2001.

    Biological: NTLA-2001

  • Experimental
    Polyneuropathy Part 2: NTLA-2001

    Participants, assigned to the dose-expansion cohort, will receive a single dose of NTLA-2001.

    Biological: NTLA-2001

  • Experimental
    Cardiomyopathy Part 1 (UK only): NTLA-2001

    Participants, assigned to one of 2 dose-escalation cohorts, will receive a single dose of NTLA-2001.

    Biological: NTLA-2001

  • Experimental
    Cardiomyopathy Part 2 (UK only): NTLA-2001

    Participants, assigned to the dose-expansion cohort, will receive a single dose of NTLA-2001.

    Biological: NTLA-2001

  • Experimental
    Polyneuropathy Follow-on Dosing (PN Part 1 Dose Level 1 Subjects only): NTLA-2001

    Participants assigned to the follow-on dosing cohort will receive a subsequent dose of NTLA-2001.

    Biological: NTLA-2001

Interventions

  • BiologicalNTLA-2001

    A clustered regularly interspaced short palindromic repeats (CRISPR)/Cas9 gene editing system delivered by lipid nanoparticles (LNPs) for intravenous (IV) administration

06

What researchers measure

Primary outcomes

  1. Number of Participants with Treatment-Emergent Adverse Events

    Time frame: up to Day 730

  2. Number of Participants with Clinically Significant Clinical Laboratory Test Findings

    Time frame: up to Day 730

  3. Number of Participants with Clinically Significant Safety Measurements

    Time frame: up to Day 730

  4. Percent Change from Baseline in Serum TTR (enzyme-linked immunosorbent assay [ELISA])

    Time frame: up to Day 730

  5. Percent Change from Baseline in Serum Prealbumin

    Time frame: up to Day 730

  6. Mean Area Under the Plasma Concentration-Time Curve from Time Zero to the Time of the Last Measurable Concentration (AUClast) for DMG-PEG2k, LP000001, Cas9 mRNA, and sgRNA

    Time frame: up to Day 730

  7. Mean Area Under the Plasma Concentration-Time Curve from Time Zero to Infinity (AUCinf) for DMG-PEG2k, LP000001, Cas9 mRNA, and sgRNA

    Time frame: up to Day 730

  8. Mean Maximum Concentration (Cmax) for DMG-PEG2k, LP000001, Cas9 mRNA, and sgRNA

    Time frame: up to Day 730

  9. Mean Time of the Maximum Concentration (Tmax) for DMG-PEG2k, LP000001, Cas9 mRNA, and sgRNA

    Time frame: up to Day 730

  10. Mean Terminal Half-Life (t½) for DMG-PEG2k, LP000001, Cas9 mRNA, and sgRNA

    Time frame: up to Day 730

  11. Mean Apparent Clearance (CL) for DMG-PEG2k, LP000001, Cas9 mRNA, and sgRNA

    Time frame: up to Day 730

  12. Mean Volume of Distribution (Vd) for DMG-PEG2k, LP000001, Cas9 mRNA, and sgRNA

    Time frame: up to Day 730

  13. Change from Baseline in Anti-Drug Antibody to NTLA-2001 and Anti-Cas9 Protein Antibody to Transgene Product Levels

    Time frame: up to Day 730

Secondary outcomes

  1. Polyneuropathy only: Change from Baseline in Familial Amyloid Polyneuropathy (FAP) Stage.

    Time frame: up to Day 730

  2. Polyneuropathy only: Change from Baseline in Polyneuropathy Disability (PND) Score

    Time frame: up to Day 730

  3. Polyneuropathy only: Change from Baseline in Modified Body Mass Index (mBMI)

    Time frame: up to Day 730

  4. Polyneuropathy only: Change from Screening in Neuropathy Impairment Score (NIS)

    Time frame: up to Day 730

  5. Polyneuropathy only: Change from Baseline in Modified Neuropathy Impairment Score +7 (mNIS+7)

    Time frame: up to Day 730

  6. Polyneuropathy only: Change from Screening in 10-Meter Walk Test (10-MWT)

    Time frame: up to Day 730

  7. Polyneuropathy only: Change from Baseline in Norfolk Quality of Life-Diabetic Neuropathy (QOL-DN)

    Time frame: up to Day 730

  8. Polyneuropathy only: Change from Baseline in EuroQOL (EQ)-5D-5L

    Time frame: up to Day 730

  9. Cardiomyopathy only: Change from Baseline in N-terminal prohormone of brain natriuretic peptide (NT-proBNP)

    Time frame: up to Day 730

  10. Cardiomyopathy only: Change from Baseline in hs Troponin T

    Time frame: up to Day 730

  11. Cardiomyopathy only: Change from Baseline in Magnetic resonance imaging (MRI)

    Time frame: up to Day 730

  12. Cardiomyopathy only: Change from Baseline in Echocardiogram

    Time frame: up to Day 730

  13. Cardiomyopathy only: Change from Baseline in Cardio-pulmonary exercise test

    Time frame: up to Day 730

  14. Cardiomyopathy only: Change from Baseline in 6-Minute Walk Test (6-MWT)

    Time frame: up to Day 730

  15. Cardiomyopathy only: Change from Baseline in New York Heart Association (NYHA) Classification

    Time frame: up to Day 730

  16. Cardiomyopathy only: Change from Baseline in Patient-reported outcomes (KCCQ)

    Time frame: up to Day 730

07

Study locations

4 sites
  • Clinical Trial Site
    Paris, France
  • Clinical Trial Site
    Auckland, New Zealand
  • Clinical Trial Site
    Umeå, Sweden
  • Clinical Trial Site
    London, United Kingdom
08

References and documents

Publications

  • Gillmore JD, Gane E, Taubel J, Pilebro B, Echaniz-Laguna A, Kao J, Litchy W, Shahda S, Haagensen A, Walsh L, Smith D, Kachadourian J, Ward JH, Lebwohl D, Zhu P, Xu Y, Leung A, Sonderfan A, Gutstein DE, Manvelian G, Adams D. Nexiguran Ziclumeran Gene Editing in Hereditary ATTR with Polyneuropathy. N Engl J Med. 2025 Oct 9;393(14):1375-1386. doi: 10.1056/NEJMoa2510209. Epub 2025 Sep 25. PubMed 41002250 ↗
  • Fontana M, Solomon SD, Kachadourian J, Walsh L, Rocha R, Lebwohl D, Smith D, Taubel J, Gane EJ, Pilebro B, Adams D, Razvi Y, Olbertz J, Haagensen A, Zhu P, Xu Y, Leung A, Sonderfan A, Gutstein DE, Gillmore JD. CRISPR-Cas9 Gene Editing with Nexiguran Ziclumeran for ATTR Cardiomyopathy. N Engl J Med. 2024 Dec 12;391(23):2231-2241. doi: 10.1056/NEJMoa2412309. Epub 2024 Nov 16. PubMed 39555828 ↗
  • Gillmore JD, Gane E, Taubel J, Kao J, Fontana M, Maitland ML, Seitzer J, O'Connell D, Walsh KR, Wood K, Phillips J, Xu Y, Amaral A, Boyd AP, Cehelsky JE, McKee MD, Schiermeier A, Harari O, Murphy A, Kyratsous CA, Zambrowicz B, Soltys R, Gutstein DE, Leonard J, Sepp-Lorenzino L, Lebwohl D. CRISPR-Cas9 In Vivo Gene Editing for Transthyretin Amyloidosis. N Engl J Med. 2021 Aug 5;385(6):493-502. doi: 10.1056/NEJMoa2107454. Epub 2021 Jun 26. PubMed 34215024 ↗
  • Stephenson AA, Flanigan KM. Gene editing and modulation for Duchenne muscular dystrophy. Prog Mol Biol Transl Sci. 2021;182:225-255. doi: 10.1016/bs.pmbts.2021.01.029. Epub 2021 Mar 3. PubMed 34175043 ↗
09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Nov 2020 to primary completion in Sep 2025, 58 months.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 19, 2020
First posted
Oct 23, 2020
StartActual
Nov 5, 2020
Primary completionActual
Sep 12, 2025
CompletionActual
Sep 12, 2025
Last update
Jan 30, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 30, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04601051
Lead sponsor
Intellia Therapeutics
Responsible party
Sponsor
First posted
Oct 23, 2020
Start date
Nov 5, 2020
Primary completion
Sep 12, 2025
Completion
Sep 12, 2025
Last update
Jan 30, 2026

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jan 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: NTLA-2001

Start the discussion